Notably, the clinical approval of inhibitors targeting CDK4/6, whose activity is determined by cyclin D1 protein level, highlights the pronounced clinical significance of cyclin D1 in the context of cancer therapeutics, particularly for breast cancer.53 Here, CDK4 is linked to breast cancer.